



# Artisan Global Equity Fund

MONTHLY  
Commentary

Investor Class: ARTHX

As of 31 July 2020

## Commentary

Global equity markets were mixed in July. Emerging markets equities outperformed developed markets, and the US, helped by big tech, outperformed Europe and Japan. The appreciation of all G10 currencies versus the US dollar provided a tailwind for USD-based returns. The US dollar's large move lower has occurred as negative US real interest rates have declined further, and the US has had less success quelling COVID-19 compared to other major economies.

Underlying economic weakness amid the pandemic has remained counterbalanced by hopes of promising vaccine developments and a backdrop of extensive fiscal and monetary policy support globally. In July, the European Union agreed to a 750 billion euro joint stimulus plan representing a historic step toward greater fiscal integration among the 27-nation bloc as it seeks to bolster its economy and avoid another debt crisis.

Our portfolio generated a solid return for the month but trailed the MSCI AC World Index. Relative performance results were held back by underperformance among our biotechnology holdings. Detractors included ACADIA Pharmaceuticals and Idorsia. Both stocks were down due to Phase III trial results. ACADIA is a biopharmaceutical company and maker of Nuplazid® (pimavanserin), the only approved treatment for Parkinson's disease psychosis. Its trial for Nuplazid® for depression missed its primary endpoint. At this time, ACADIA does not plan to conduct another trial in this indication. Despite this outcome, we believe Nuplazid's label expansion to dementia psychosis—a large market opportunity that currently does not have any other approved drugs—remains likely.

Idorsia is a Swiss biotechnology company that was spun off from Actelion in 2017. The company has a broad clinical development pipeline, with several Phase III proprietary programs in the areas of insomnia, resistant hypertension management and Fabry disease, among others. Shares fell on mixed results for its second Phase III study for lead pipeline asset daridorexant, a dual orexin receptor antagonist for the treatment of insomnia, as statistical significance was not found at the lower dose. However, we still see a high probability of the combined Phase III dataset supporting approval for the higher dose. The stock remains a smaller position in the portfolio.

Sources of strength included our industrials gases, e-commerce and beverage holdings. Specifically, top contributors were Linde, Air Liquide, Amazon.com, Alibaba and Wuliangye Yibin. In recent quarterly letters, we've discussed the common dynamics supporting these high-quality companies, including secular tailwinds that have accelerated due to the pandemic and sustainable growth characteristics we seek in our portfolio companies: dominant industry positions, strong pricing power and a history of steady growth across the cycle.

## Portfolio Details

Net Asset Value (NAV)	\$22.04
ARTHX Inception	29 March 2010
Expense Ratios	
Semi-Annual Report 31 Mar 2020 <sup>1</sup>	1.27%
Prospectus 30 Sep 2019 <sup>2,3</sup>	1.28%

<sup>1</sup>Unaudited, annualized for the six-month period. <sup>2</sup>Reflects a reduction in management fees, effective as of 15 Nov 2019. <sup>3</sup>See prospectus for further details.

## Top 10 Holdings (% of total portfolio)

Amazon.com Inc (United States)	3.5
Linde PLC (United Kingdom)	3.4
Deutsche Boerse AG (Germany)	3.4
Fidelity National Information Services Inc (United States)	3.1
Halozyme Therapeutics Inc (United States)	2.8
Vertiv Holdings Co (United States)	2.6
Microsoft Corp (United States)	2.4
Genmab A/S (Denmark)	2.4
Alphabet Inc (United States)	2.2
Deutsche Telekom AG (Germany)	1.8
<b>TOTAL</b>	<b>27.7%</b>

Source: Artisan Partners/MSCI.

## Sector Diversification (% of total portfolio equities)

	Fund	ACWI <sup>1</sup>
Communication Services	8.0	9.4
Consumer Discretionary	6.8	12.1
Consumer Staples	4.4	8.1
Energy	0.8	3.3
Financials	8.3	13.1
Health Care	32.7	12.8
Industrials	11.7	9.3
Information Technology	20.5	21.1
Materials	5.1	4.8
Real Estate	0.0	2.8
Utilities	1.7	3.2
<b>TOTAL</b>	<b>100.0%</b>	<b>100.0%</b>

Source: Artisan Partners/GICS/MSCI. Cash and cash equivalents represented 1.0% of the total portfolio. <sup>1</sup>MSCI All Country World Index.

## Investment Results (%)

As of 31 July 2020	Average Annual Total Returns							
	MTD	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception
Investor Class: ARTHX	4.55	4.55	8.57	15.48	14.62	10.42	13.62	12.50
MSCI All Country World Index	5.29	5.29	-1.29	7.20	6.99	7.37	8.87	8.04

As of 30 June 2020	Average Annual Total Returns							
	MTD	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception
Investor Class: ARTHX	3.13	23.56	3.84	11.04	14.46	9.58	13.91	12.13
MSCI All Country World Index	3.20	19.22	-6.25	2.11	6.14	6.46	9.16	7.56

Source: Artisan Partners/MSCI. Returns for periods less than one year are not annualized.


Past performance does not guarantee and is not a reliable indicator of future results. Investment returns and principal values will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than that shown. Call 800.344.1770 for current to most recent month-end performance. Performance may reflect agreements to limit a Fund's expenses, which would reduce performance if not in effect.

## Region/Country Allocation (% of total portfolio equities)

REGION	Fund	ACWI <sup>1</sup>
<b>AMERICAS</b>	<b>55.5</b>	<b>60.7</b>
United States	52.4	57.9
Canada	3.1	2.8
<b>EUROPE</b>	<b>30.7</b>	<b>16.9</b>
Germany	8.5	2.5
Switzerland	7.1	2.8
United Kingdom	4.9	3.7
Denmark	3.3	0.7
Sweden	1.7	0.9
France	1.6	2.9
Belgium	1.2	0.3
Portugal	0.8	<0.1
Netherlands	0.7	1.2
Ireland	0.4	0.2
Spain	0.3	0.6
<b>EMERGING MARKETS</b>	<b>7.4</b>	<b>12.5</b>
China	6.7	5.2
India	0.8	1.0
<b>PACIFIC BASIN</b>	<b>6.4</b>	<b>9.6</b>
Japan	5.3	6.5
Hong Kong	1.1	0.9
<b>MIDDLE EAST</b>	<b>—</b>	<b>0.2</b>
<b>TOTAL</b>	<b>100.0%</b>	<b>100.0%</b>

Source: Artisan Partners/MSCI. <sup>1</sup>MSCI All Country World Index. Countries held in the index, but not held in the portfolio, are not listed.

## Team Leadership (Pictured left to right)



Portfolio Managers	Years of Investment Experience
Mark L. Yockey, CFA	39
Charles-Henri Hamker	30
Andrew J. Euretig	16

Carefully consider the Fund's investment objective, risks and charges and expenses. This and other important information is contained in the Fund's prospectus and summary prospectus, which can be obtained by calling 800.344.1770. Read carefully before investing.

Current and future portfolio holdings are subject to risk. International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period.

MSCI All Country World Index measures the performance of developed and emerging markets. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

For the purpose of determining the Fund's holdings, securities of the same issuer are aggregated to determine the weight in the Fund. The discussion of portfolio holdings does not constitute a recommendation of any individual security. These holdings comprise the following percentages of the Fund's total net assets as of 31 Jul 2020: ACADIA Pharmaceuticals Inc 1.5%; Air Liquide SA 1.6%; Alibaba Group Holding Ltd 1.0%; Idorsia Ltd 0.8%; Wuliangye Yibin Co Ltd 1.6%. Securities named in the Commentary, but not listed as a Top Ten Holding or not listed here are not held in the Fund as of the date of this report. The portfolio managers' views and portfolio holdings are subject to change and the Fund disclaims any obligation to advise investors of such changes.

Unless otherwise indicated, all information in this report includes all classes of shares, except performance and expense ratio information, and is as of the date shown in the upper right hand corner. Totals may not sum due to rounding.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

The Global Industry Classification Standard (GICS<sup>®</sup>) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used to create indices or financial products. This report is not approved or produced by MSCI.

Country exposure percentages reflect country designations as classified by MSCI as of the date shown. Securities not classified by MSCI reflect country designations as of the date the report was generated. Sector exposure percentages reflect sector designations as currently classified by GICS.

Artisan Partners Funds offered through Artisan Partners Distributors LLC (APDLLC), member FINRA. APDLLC is a wholly owned broker/dealer subsidiary of Artisan Partners Holdings LP. Artisan Partners Limited Partnership, an investment advisory firm and adviser to Artisan Partners Funds, is wholly owned by Artisan Partners Holdings LP.

© 2020 Artisan Partners. All rights reserved.

